Updated Results of a Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia


Updated Results of a Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Slides from presentations at ASCO 2013/ICML 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (9/10/13)

Seymour JF et al. Updated results of a Phase I first-in-human study of the Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc ASCO 2013;Abstract 7018.

Seymour J et al. Updated results of a Phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Proc ICML 2013;Abstract 057.

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.